MONTREAL, CANADA / ACCESSWIRE / December 17, 2018 / Sunshine Biopharma, Inc. (OTC PINK: "SBFM") today announced
that it has received Health Canada approval for Essential 9TM, the first in a line of essential micronutrients products that the
Company is planning to launch. On Friday December 14, 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine
Biopharma to manufacture and sell the Essential 9TM product. Essential 9TM are dietary supplement tablets that contain a balanced
formula of the 9 essential amino acids that the human body cannot make. Sunshine Biopharma anticipates to start shipping Essential
9TM in the second week of January 2019.
About Essential 9TM
Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body
functions – From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot
be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to
loss of muscle mass, fatigue, weight gain and reduced ability to build muscle mass in athletes. Sunshine Biopharma's Essential 9TM
provides all 9 Essential Amino Acids in free form and in the proportions recommended by Health Canada. Essential 9TM is suitable
for everyone: vegans, athletes, seniors, dieters.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue
projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions,
future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or
otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain
risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
SOURCE: Sunshine Biopharma, Inc.
